Composition For Treating Tauopathy In The Brain, Brain Stem and Spinal Column

Abstract

A composition of matter comprising an α-ketoglutarate (AKG) or an α-ketoglutaric acid or a salt of an α-ketoglutarate may be used to treat patients having a neurodegenerative disease, such as amyotrophic lateralsclerosis. The composition may be administered hourly or may be administered once a day depending on the size and activity of the patient and the release coating or mechanism provided. In addition to AKG, a core composition may comprise GABA and a source of coenzyme Q10. Other substances may be provided either orally or intravenous in addition to the core composition, as required to control symptoms, or in order to stimulate stem cells to add motor neurons.

1 . A nutritional supplement for those suffering from a neurodegenerative disease characterized by tauopathy in the brain, brain stem and spinal column, the nutritional supplement comprising: a serving of a base composition with 3-9 grams of alpha-ketoglutarate and an amount of y-aminobutyric acid (GABA) of at least 50 mg and not more than 140 mg per serving of the composition, wherein the GABA has the chemical formula: 
       
         
           
           
               
               
           
         
         with a free amino group and a free carboxylic acid group when dissolved in water; and 
         the serving of the base composition is taken orally three times per day as a supplement for those suffering from a neurodegenerative disease characterized by tauopathy in the brain, brain stem or spinal column. 
       
     
     
         2 . The nutritional supplement of  claim 1  wherein the serving of the base composition further comprises a therapeutically effective amount of a form of coenzyme Q10. 
     
     
         3 . The nutritional supplement of  claim 2  wherein the serving of the base composition further comprises a nicotinamide. 
     
     
         4 . The nutritional supplement of  claim 3 , wherein the nicotinamide comprises NADH. 
     
     
         5 . The nutritional supplement of  claim 3 , wherein the nicotinamide comprises niacin. 
     
     
         6 . The nutritional supplement of  claim 1 , wherein the α-ketoglutarate comprises an arginine-α-ketoglutarate. 
     
     
         7 . The nutritional supplement of  claim 6 , wherein the α-ketoglutarate further comprises a glycine-α-ketoglutarate. 
     
     
         8 . The nutritional supplement of  claim 6 , wherein the α-ketoglutarate further comprises a magnesium-α-ketoglutarate. 
     
     
         9 . The nutritional supplement of  claim 1 , wherein the base composition further comprises a caprylic acid. 
     
     
         10 . The nutritional supplement of  claim 1 , further comprising packaging the base composition in single serving packages. 
     
     
         11 . The nutritional supplement of  claim 1 , further comprising preparing the base composition by combining a source of the α-ketoglutarate (AKG) in a therapeutically effective amount with a source of the γ-aminobutyric acid (GABA) in a therapeutically effective amount as constituents in a powder mixture or liquid serving mixture. 
     
     
         12 . A nutritional supplement for those suffering from a neurodegenerative disease characterized by tauopathy in the brain, brain stem and spinal column, the nutritional supplement comprising:
 a base composition, taken orally three times daily, wherein the base composition comprises a mixture of:
 3-9 grams of an arginine α-ketoglutarate (alpha-ketoglutarate) as a salt or other orally administered composition; and 
 at least 50 mg and not more than 140 mg per serving of a γ-aminobutyric acid (GABA) having a chemical formula: 
   
       
         
           
           
               
               
           
         
       
       with a free amino group and a free carboxylic acid group, when the composition is dissolved in water.